NCT06853015
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
Recruiting
PHASE1Ages 18–85InterventionalTreatmentShirley Ryan AbilityLabInvestigator-initiated
~27 participants
Updated 2026-06-03 on ClinicalTrials.gov
What's tested:DalfampridinePlaceboSTDP stimulationExercise training
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in TMEPs
Measured over TMEPs measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Study leadership
- Monica Perez, PT, PhD · PRINCIPAL_INVESTIGATOR · Shirley Ryan Ability Lab
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male and females between ages 18-85 years
SCI 6 months post injury
Spinal Cord injury at or above L2
ASIA A, B, C, or D, complete or incomplete
The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles
Exclusion
Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease
Any history of renal impairment
Any debilitating disease prior to the SCI that caused exercise intolerance
Premorbid, ongoing major depression or psychosis, altered cognitive status
History of head injury or stroke
Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
History of seizures or epilepsy
Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)
Pregnant females
If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test
Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
Metal plate in skull
Individuals with scalp shrapnel, cochlear implants, or aneurysm clips
Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs
What this trial measures
- Change in TMEPsTMEPs measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Electrical stimulation will be performed placing the cathode on the upper thoracic between the spinal processes between T3 and T4 vertebrae and the anode at \~10 cm above
- Change in MVCMVC measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Individuals will perform a maximum voluntary contraction (MVC) of each targeted muscle (quadriceps femoris, tibialis anterior or soleus) through surface electrodes secured to the skin over the belly of each muscle. Ankle flexion torque will be measured by measured by force sensors.